Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5AP known ✓ | P20292 | 20/20 | 0.78 |
| ▸ | PTGS1 known ✓ | P23219 | 3/20 | 0.78 |
| ▸ | ALOX5 known ✓ | P09917 | 1/20 | 0.78 |
| ▸ | LTC4S | Q16873 | 1/20 | 0.78 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.68 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29617637 | 1.00 | ALOX5AP (0.78) | ALOX5APPTGS1ALOX5LTC4SCYP3A4 | |
| Fiboflapon SCHEMBL29526863 | 0.95 | ALOX5AP (0.87) | ALOX5APPTGS1ALOX5LTC4SCYP3A4 | |
| Fiboflapon SCHEMBL1254527 | 0.95 | ALOX5AP (0.87) | ALOX5APPTGS1ALOX5LTC4SCYP3A4 | |
| Fiboflapon SCHEMBL1394726 | 0.93 | ALOX5AP (0.87) | ALOX5APPTGS1ALOX5LTC4SCYP3A4 | |
| Fiboflapon SCHEMBL1254870 | 0.93 | ALOX5AP (0.87) | ALOX5APPTGS1ALOX5LTC4SCYP3A4 | |
| SCHEMBL167903 | 0.93 | ALOX5AP (0.90) | ALOX5APPTGS1ALOX5LTC4SCYP3A4 | |
| SCHEMBL29063029 | 0.93 | ALOX5AP (0.88) | ALOX5APPTGS1ALOX5LTC4SCYP3A4 | |
| SCHEMBL3057387 | 0.91 | ALOX5AP (0.77) | ALOX5APPTGS1ALOX5LTC4SCYP3A4 | |
| SCHEMBL1722524 | 0.88 | ALOX5AP (1.00) | ALOX5APPTGS1ALOX5LTC4S | |
| Fiboflapon SCHEMBL29723363 | 0.88 | ALOX5AP (1.00) | ALOX5APPTGS1ALOX5LTC4SCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260138988-A1 | Spiropyrrolidine Derived Antiviral Agents | ENANTA PHARMACEUTICALS INC (US) | 2026-05-21 | — | — | US | disclosed |
| US-20260116857-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOFS | PARDES BIOSCIENCES INC (US) | 2026-04-30 | — | — | US | disclosed |
| US-12570663-B2 | Crystal forms of an anti-sars CoV-2 agent | ENANTA PHARMACEUTICALS, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| US-12540141-B2 | Spiropyrrolidine derived antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2026-02-03 | — | — | US | disclosed |
| US-12479854-B2 | Spiropyrrolidine derived antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2025-11-25 | — | — | US | disclosed |
| EP-4635972-A2 | FUNCTIONALIZED PEPTIDES AS ANTIVIRAL AGENTS | Enanta Pharmaceuticals, Inc. (US) | 2025-10-22 | — | — | EP | disclosed |
| US-12398147-B2 | Macrocyclic spiropyrrolidine derived antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2025-08-26 | — | — | US | disclosed |
| EP-4051265-B1 | FUNCTIONALIZED PEPTIDES CONTAINING TWO PYRROLIDINE RINGS AS ANTICORONAVIRUS AGENTS | ENANTA PHARM INC (US) | 2025-08-20 | — | — | EP | disclosed |
| US-20250154163-A1 | Pyrimidinone-Containing 17-Beta-Hydroxysteroid Dehydrogenase Type 13 Inhibitors | ENANTA PHARMACEUTICALS, INC. | 2025-05-15 | — | — | US | disclosed |
| US-12162857-B2 | Antiviral compounds | ENANTA PHARMACEUTICALS, INC. (US) | 2024-12-10 | — | — | US | disclosed |
| US-11312704-B2 | Inhibitors of cysteine proteases and methods of use thereof | Pardes Biosciences, Inc. (US) | 2022-04-26 | — | — | US | disclosed |
| US-20220073499-A1 | FUNCTIONALIZED PEPTIDES AS ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2022-03-10 | — | — | US | disclosed |
| US-20220048944-A1 | FUNCTIONALIZED PEPTIDES AS ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2022-02-17 | — | — | US | disclosed |
| US-20220041652-A1 | FUNCTIONALIZED PEPTIDES AS ANTIVIRAL AGENTS | ENANTA PHARM INC (US) | 2022-02-10 | — | — | US | disclosed |
| US-20220033383-A1 | FUNCTIONALIZED PEPTIDES AS ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2022-02-03 | — | — | US | disclosed |
| US-20210355111-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. | 2021-11-18 | — | — | US | disclosed |
| WO-2021231778-A1 | CORONAVIRUS PROTEASE DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2021-11-18 | — | — | WO | disclosed |
| US-11174231-B1 | Inhibitors of cysteine proteases and methods of use thereof | Pardes Biosciences, Inc. (US) | 2021-11-16 | — | — | US | disclosed |
| US-11124497-B1 | Inhibitors of cysteine proteases and methods of use thereof | Pardes Biosciences, Inc. (US) | 2021-09-21 | — | — | US | disclosed |
| WO-2018042343-A2 | COMPOUNDS THAT INHIBIT 3C AND 3CL PROTEASES AND METHODS OF USE THEREOF | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2018-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (16 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12570663-B2 | Crystal forms of an anti-sars CoV-2 agent | RNGTT, SARS1, POLM | ALOX5AP 2987/4885PTGS1 1941/4885ALOX5 4104/4885 |
| US-20260138988-A1 | Spiropyrrolidine Derived Antiviral Agents | ACE, ACE2, TMPRSS2 | ALOX5AP 1086/4885PTGS1 1307/4885ALOX5 1828/4885 |
| US-20260116857-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOFS | CTRC, CTRL, CTSL | ALOX5AP 3193/4885PTGS1 2054/4885ALOX5 1961/4885 |
| US-11312704-B2 | Inhibitors of cysteine proteases and methods of use thereof | CTSV, CTRL, CTSL | ALOX5AP 2056/4885PTGS1 1172/4885ALOX5 1716/4885 |
| US-20220041652-A1 | FUNCTIONALIZED PEPTIDES AS ANTIVIRAL AGENTS | SARS1, VIP, ACE | ALOX5AP 3432/4885PTGS1 3199/4885ALOX5 3512/4885 |
| US-12162857-B2 | Antiviral compounds | ACE, ZC3HAV1, SARS1 | ALOX5AP 939/4885PTGS1 531/4885ALOX5 1035/4885 |
| US-20220048944-A1 | FUNCTIONALIZED PEPTIDES AS ANTIVIRAL AGENTS | SARS1, VIP, ACE | ALOX5AP 3432/4885PTGS1 3199/4885ALOX5 3512/4885 |
| US-12398147-B2 | Macrocyclic spiropyrrolidine derived antiviral agents | ACE, ACE2, PKD1 | ALOX5AP 3057/4885PTGS1 993/4885ALOX5 2831/4885 |
| US-20220073499-A1 | FUNCTIONALIZED PEPTIDES AS ANTIVIRAL AGENTS | SARS1, VIP, ACE | ALOX5AP 3432/4885PTGS1 3199/4885ALOX5 3512/4885 |
| US-20210355111-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | CTRL, CTSV, CTSL | ALOX5AP 1808/4885PTGS1 1416/4885ALOX5 1789/4885 |
| US-11124497-B1 | Inhibitors of cysteine proteases and methods of use thereof | CTRL, CTSV, CTSL | ALOX5AP 3251/4885PTGS1 1405/4885ALOX5 2911/4885 |
| US-11174231-B1 | Inhibitors of cysteine proteases and methods of use thereof | CTRL, CTSV, CTSL | ALOX5AP 1808/4885PTGS1 1416/4885ALOX5 1789/4885 |
| US-12479854-B2 | Spiropyrrolidine derived antiviral agents | ACE, ACE2, PKD1 | ALOX5AP 2349/4885PTGS1 516/4885ALOX5 2293/4885 |
| US-12540141-B2 | Spiropyrrolidine derived antiviral agents | ACE2, NR3C2, ACE | ALOX5AP 4346/4885PTGS1 1200/4885ALOX5 3791/4885 |
| US-20250154163-A1 | Pyrimidinone-Containing 17-Beta-Hydroxysteroid Dehydrogenase Type 13 Inhibitors | HSD17B13, HSD17B1, HSD11B1 | ALOX5AP 1615/4885PTGS1 303/4885ALOX5 506/4885 |
| US-20220033383-A1 | FUNCTIONALIZED PEPTIDES AS ANTIVIRAL AGENTS | SARS1, VIP, ACE | ALOX5AP 3432/4885PTGS1 3199/4885ALOX5 3512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.